1 Title: SARS-CoV-2 Seroepidemiology in Children and Adolescents

- 2 Rebecca E Levorson, Erica Christian, Brett Hunter, Jasdeep Sayal, Jiayang Sun, Scott A Bruce,
- 3 Stephanie Garofalo, Matthew Southerland, Svetlana Ho, Shira Levy, Christopher Defillipi, Lilian
- 4 Peake, Frederick C Place*, Suchitra K Hourigan*
- 5 *Authors contributed equally

- Rebecca E Levorson, MD. Inova Children's Hospital. 3300 Gallows Rd, Falls Church,
 VA 22042. and Pediatric Specialists of Virginia, 3023 Hamaker Court, Fairfax, VA
 22031.
- Erica Christian, MS. Inova Children's Hospital. 3300 Gallows Rd, Falls Church, VA
 22042
- Brett Hunter, PhD. Department of Statistics, George Mason University. 4400 University
 Dr, Fairfax, VA 22030
- Jasdeep Sayal, MBA. Inova Children's Hospital. 3300 Gallows Rd, Falls Church, VA
 22042
- Jiayang Sun, PhD. Department of Statistics, George Mason University. 4400 University
 Dr, Fairfax, VA 22030
- Scott A Bruce, PhD. Department of Statistics, George Mason University. 4400 University
 Dr, Fairfax, VA 22030
- 7. Stephanie Garofalo, RN. Inova Heart and Vascular Institute. 3300 Gallows Rd, Falls
 Church, VA 22042.
- 8. Matthew Southerland, BS. Inova Heart and Vascular Institute. 3300 Gallows Rd, Falls
 Church, VA 22042.
- 9. Svetlana Ho, MD. Inova Children's Hospital. 3300 Gallows Rd, Falls Church, VA 22042
- 25 10. Shira Levy, MA. Inova Children's Hospital. 3300 Gallows Rd, Falls Church, VA 22042
- 26 11. Christopher Defillipi, MD. Inova Heart and Vascular Institute. 3300 Gallows Rd, Falls
 27 Church, VA 22042.
- 12. Lilian Peake, MD, MPH. Virginia Department of Health. 109 Governor Street,
 Richmond, VA 23219.
- 30 13. Frederick C Place, MD. Inova Children's Hospital. 3300 Gallows Rd, Falls Church, VA
 31 22042
- 14. Suchitra K Hourigan, MD. Inova Children's Hospital. 3300 Gallows Rd, Falls Church,
 VA 22042 and Pediatric Specialists of Virginia, 3023 Hamaker Court, Fairfax, VA
 22031..
- 35
- Corresponding author: Suchitra K Hourigan, MD. Inova Children's Hospital. 3300 Gallows
 Rd, Falls Church, VA 22042. Email:suchihourigan@gmail.com. Tel: 410-917-3331.
- 38
- **Short title:** SARS-CoV-2 Seroepidemiology in Children
- 40
- 41

42

43 **Conflict of Interest Disclosures:**

Author Christopher Defillipi consults for Ortho Diagnostics, Abbott Diagnostics, and Siemens
 Healthineers. No other authors have any conflicts of interest relevant to this article to disclose.

46 Funding/Support and Role of Funder:

47 The Virginia Department of Health provided funding for this study. The Virginia Department of Health, in conjunction with the authors of this manuscript, were involved in study design, the 48 writing of the report and the decision to submit the paper for publication. The Virginia 49 Department of Health were not involved in collection, analysis or interpretation of the data. 50 Research reported in this publication was also supported in part by the National Institute of Child 51 52 Health and Human Development under Award Number K23HD099240 (Hourigan). Research 53 reported in this publication was also supported in part via a subcontract from the parent award by the National Center for Advancing Translational Sciences of the National Institutes of Health 54 under Award Number UL1TR003015 (Hunter, Sun, Bruce). The content is solely the 55 56 responsibility of the authors and does not necessarily represent the official views of the National 57 Institutes of Health.

58

Article Summary: 8.5% of children had SARS-CoV-2 antibodies in Fall 2020, double the adult rate. The role of pediatric infection is important to consider in mitigation strategies.

61 What's Known on This Subject:

SARS-CoV-2 pediatric seroepidemiologic data is limited. Reported viral rates underestimate the
 burden of infection in children due to mild or asymptomatic disease. Limited cohorts of children
 suggest low seropositivity rates compared to adults.

65 What This Study Adds:

US children in the largest SARS-CoV-2 seroepidemiology study to date had double the rate of
antibodies compared to adults. Most children were asymptomatic. Risk factors include age,
ethnicity and living conditions. Most children made antibodies to different antigens of SARSCoV-2.

- 70
- 71
- 72
- 73
- 74

75

76 Contributor's Statement

- Dr Levorson, Dr Place and Dr Hourigan conceptualized and designed the study, enrolled
 subjects, and/or collected clinical samples and data, drafted the initial manuscript and reviewed
 and revised the manuscript.
- Ms Christian, Ms Sayal, Ms Levy and Dr Ho enrolled subjects, and/or collected clinical samples
 and data and reviewed and revised the manuscript.
- Dr Hunter, Dr Sun and Dr Bruce conceptualized and designed the study, performed statistical
 analyses of the data and reviewed and revised the manuscript.
- 84 Mr Southerland performed and provided oversight of laboratory analyses and reviewed and 85 revised the manuscript.
- Ms Garofalo, Dr Defillipi and Dr Peake conceptualized and designed the study and reviewed and
 revised the manuscript.
- All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
- 90
- 91 92 93 94 95 96 97 98

100

101 Abstract

Objectives: Pediatric SARS-CoV-2 data remain limited and seropositivity rates in children were
 reported as <1% early in the pandemic. Seroepidemiologic evaluation of SARS-CoV-2 in
 children in a major metropolitan region of the United States was performed.

105 **Methods:** Children and adolescents \leq 19 years were enrolled in a cross-sectional, observational 106 study of SARS-CoV-2 seroprevalence from July-October 2020 in Northern Virginia, United 107 States. Demographic, health, and COVID-19 exposure information was collected, and blood was 108 analyzed for SARS-CoV-2 spike protein total antibody. Risk factors associated with SARS-109 CoV-2 seropositivity were analyzed. Orthogonal antibody testing was performed, and samples 110 were evaluated for responses to different antigens.

Results: In 1038 children, the anti-SARS-CoV-2 total antibody positivity rate was 8.5%. After multivariate logistic regression, significant risk factors included Hispanic ethnicity, public or absent insurance, a history of COVID-19 symptoms, exposure to person with COVID-19, a household member positive for SARS-CoV-2 and multi-family or apartment dwelling without a private entrance. 66% of seropositive children had no symptoms of COVID-19. Orthogonal antibody testing with a receptor binding domain specific antigen revealed a high concordance of 80.5%. Children also demonstrated a robust immune response to the nucleocapsid antigen.

118 **Conclusions:** A much higher burden of SARS-CoV-2 infection, as determined by seropositivity, 119 was found in children than previously reported; this was also higher compared to adults in the 120 same region at a similar time. Contrary to prior reports, we determined children shoulder a 121 significant burden of COVID-19 infection. The role of children's disease transmission must be 122 considered in COVID-19 mitigation strategies including vaccination.

123

124 Key Words: COVID-19; SARS-CoV-2; serology; antibody; seroprevalence; children; pediatrics

- 125
- 126
- 127
- 128
- 129
- 130

131

132 Introduction

Current epidemiologic data in the United States (US) and globally indicating sustained community transmission of SARS-CoV-2 is indisputable. The extent of SARS-CoV-2 community transmission remains incompletely understood, particularly regarding children. Initially, our understanding was dependent upon aggregate molecular testing for acute infection and largely missed mild and asymptomatic infections. Based on this data, early reports misleadingly suggested that children were largely spared infection from SARS-CoV-2 [1,2].

139 Seroprevalence estimates can be useful to understand the true cumulative incidence in a given population. 140 Antibody seropositivity provides data about asymptomatic or subclinical infections that would not be 141 detected by surveillance relying on interactions with the health care system. Limited pediatric seroprevalence data exist for SARS-CoV-2. Following the first pandemic wave in Spain, up to a 6.2% 142 143 seropositivity was reported late April/early May 2020, with only 3.8% of children aged 0-19 years being 144 seropositive [3]. Antibody positivity in a smaller population-based study in Switzerland in mid-May 2020 145 was lowest in children 0-9 years at 0.8%, compared with adults aged 20-49, at 9.9% [4]. Similarly, in 146 Germany a low seropositivity rate of 0.6% was reported in children aged 1-10 years [5],

An investigation in spring 2020 evaluated children for SARS-CoV-2 antibodies 8-10 weeks after a large school outbreak in Santiago, Chile. Anti-SARS-CoV-2 antibodies were present in 10% of children, whereas 17% of adult staff were seropositive. Forty percent of seropositive children were categorized as asymptomatic [6]. Outside of this outbreak associated investigation, there have been no large pediatric focused seroprevalence studies in the Americas.

Compared to adults, preliminary evidence in children suggests a distinct antibody response to SARS-CoV-2 infection, with a reduced breadth of anti-SARS-CoV-2 antibodies, specifically a reduction in antinucleocapsid antibody production [7]. Furthermore, the possibility has been raised that children may have

a higher prevalence of antibodies against the S2 unit of the SARS-CoV-2 spike protein, which may be
partially due to cross-reactivity to conserved epitopes in benign seasonal human coronaviruses [8].

As there is extremely limited data regarding the burden of SARS-CoV-2 infection in children, especially in the US, the primary objective of this study was to determine SARS-CoV-2 seroprevalence in children residing in Northern Virginia in the US. Northern Virginia is the most populous and urbanized region of Virginia and is geographically linked to the Washington, D.C. metropolitan area. Secondary objectives included identification of risk factors associated with SARS-CoV-2 seropositivity in children, orthogonal antibody testing to assess the accuracy of antibody testing in children and evaluation of immunologic responses to different antigens of SARS-CoV-2 in children.

164

165 Methods

166 Children and adolescents were enrolled in this cross-sectional, observational study over a 10-week period, 167 from July 31 to October 13, 2020. Verbal informed consent was obtained from parents and adolescents 168 ≥18 years. The Inova Health Systems Human Research Protection Office waived ethics approval as per 169 CFR 45 46.102, as this project was a public health surveillance activity, funded by the Virginia 170 Department of Health (VDH). During the study period, public schools in Northern Virginia were closed 171 to in-person learning although, some childcare facilities remained open. An indoor mask mandate outside 172 the home was in effect; however, this was only for children ≥10 years and adults.

Subjects were recruited from three settings in Northern Virginia: 1) non-emergency health care settings (including pediatric primary care offices, pediatric specialty clinics and pre-surgical areas for elective procedures); 2) self-referral in response to advertisement of the study, and 3) the Inova Children's Hospital Pediatric Emergency Department and limited enrollment from inpatient units. Inclusion criteria were ≤ 19 years (the age range defined as a child for COVID-19 reporting by the state of Virginia) and residence in Virginia. Only one individual per household was permitted to enroll in the study. Exclusion

criteria included receipt of immunoglobulin therapy within the past 11 months, including intravenous
immunoglobulin, whole blood, fresh frozen plasma, experimental therapy with convalescent plasma, or
other blood product transfusions, except for packed red blood cells and platelets.

182 Enrolled participants completed a questionnaire collecting demographic, health and potential COVID-19 183 exposure information. Blood was collected by venipuncture, either for the sole purpose of the study or in conjunction with another clinical blood draw. Blood was tested using the US Food and Drug 184 185 Administration emergency use authorized Ortho Clinical Diagnostics VITROS Immunodiagnostic 186 Products Anti-SARS-CoV-2 Total test (Ortho Clinical) performed on the Vitros 3600 system (Ortho 187 Clinical Diagnostics, Raritan, NJ) to detect total antibody (IgG, IgA and IgM) responses against the 188 SARS-CoV-2 spike protein. This assay has a reported clinical specificity of 100% (95% CI: 99.1-100%) 189 [9]. Samples were documented as reactive (≥ 1.00 S/Co) or non-reactive (< 1.00 S/Co) for anti-SARS-190 CoV-2.

191 Orthogonal antibody testing was performed on reactive samples as the estimated prevalence prior to the 192 study was 1%, based on very limited data at the time.⁴ Orthogonal serologic testing was recommended by 193 the CDC for populations with a low pre-test probability, including low or unknown prevalence of disease 194 [10]. In such conditions, an initial antibody assay is performed, and then on all positive tests, a secondary assay with a different or more focused target is performed. In this study, the Ortho Clinical assay 195 196 (targeting the total protein - S1 and S2 subunits) was used as the primary assay, followed by the Siemens 197 SARS-CoV-2 IgG assay solely targeting the S1 unit receptor binding domain (RBD) (Siemens 198 Healthineers, Erlangen, Germany). Additionally, to assess the antibody response in children to different 199 SARS-CoV-2 antigens, all initially reactive samples were tested using the Abbot nucleocapsid IgG 200 antibody assay (Abbott Laboratories, Chicago, IL). Furthermore, a random 10% sample of the initial 201 non-reactive samples on the Ortho Clinical assay were analyzed on the Siemens (RBD) and Abbot 202 (nucleocapsid) IgG assays.

Sample size justification was based on early estimates suggesting a SARS-CoV-2 seroprevalence in children of approximately 1% [4]. Thus, in order to estimate the seropositivity in demographic subgroups while considering the clustering effect due to testing at different enrollment sites, 80% Wilson score intervals were used to determine a total sample size of at least 1,000 children.

207 Statistical analysis methods included both comprehensive descriptive statistics and statistical modeling. 208 Positive frequency counts were used to estimate both the overall and subgroup prevalence rates to 209 delineate the effects of different factors. The corresponding Wilson score intervals provided the 210 uncertainty quantification of the prevalence estimates. Graphical diagnostics and chi-squared tests of 211 independence were used to determine whether selected covariates were correlated. Univariate and 212 multivariate logistic regression analyses of antibody presence were used to explore potential effects from 213 covariates. A final logistic regression model was chosen using a stepwise model selection. Odds ratios 214 with corresponding confidence intervals were calculated for the coefficients in the model. The 215 distribution of antibody titer levels across different factor levels was examined. Kruskal-Wallis tests were 216 used to determine if these distributions differed across potential risk factors. Simple inter-rater reliability 217 rates were calculated to assess orthogonal testing results. R version 4.0.3 was used to perform statistical 218 analyses.

219 **Results**

This study included 1038 children. Demographic and clinical data are shown in Table 1. All age groups
between 0–19 years were well represented, and racial and ethnic diversity was reflective of the Northern
Virginia populace.

Table 1 shows the prevalence rates for anti-SARS-CoV-2 total antibody (Ortho Clinical assay) across demographic and clinical covariates of interest. The overall positivity rate for anti-SARS-CoV-2 total antibody was 8.5% (88/1038). SARS-CoV-2 antibodies were found in 8.2% of White children, 5.2% of Black or African American children, 5.7% of Asian children, and 16.2% of children identified as other

racial origin. When compared by age groups a bimodal distribution was noted with a seropositive rate of
13.7% in young children 0–5 years, 7.5% in school-age children 6–10 years, 5.1% in early adolescents
11–15 years and 10.8% in older adolescents 16–19 years (Supplemental Figure 1).

Especially high prevalence rates were noted in children with Hispanic ethnicity (26.8%, 55/207), those with public insurance (Medicaid, 21.6% 27/125), those without insurance (55.0%, 11/20), children living in multi-family or apartment dwellings without a private entrance (28.7%, 33/115), and children recruited from safety net primary care clinic (primary care location 2, 25%, 16/64) (Figure 1).

Of children exposed to an individual with a known history of COVID-19, 33.0% (35/106) had antibodies. Living in the same household with a person who tested positive for SARS-CoV-2 increased the seroprevalence rate to 52.5% (31/59). Having a personal history of symptoms consistent with COVID-19 was associated with a seroprevalence of 11.8% (30/255). However, 65.9% (58/88) of children with positive antibody testing had no personal history of symptoms, and 54.6% (48/88) had no known exposure.

After multiple regression, significant factors associated with seropositivity were found to include ethnicity, age group, insurance status, symptoms consistent with COVID-19, having a household member test positive for COVID-19 and dwelling type (Table 2).

A final multivariate logistic regression model was chosen using stepwise model selection. Remaining significant predictors included Hispanic ethnicity, lack of insurance or public insurance, a history of symptoms suggestive of COVID-19, exposure to an individual with a history of COVID-19, a household member testing positive for COVID-19, and living in a multi-family or apartment dwelling without private entrance (Table 3).

Of those who tested positive for anti-SARS-CoV-2, titer levels ranged from 1.05 to 1000 S/Co. Across all age groups, titer levels did not significantly differ (Kruskal-Wallis, p=0.088) (Supplemental Figure 2). There was no significant difference in titer levels between those with no symptoms, those with symptoms

within 2 weeks of testing, and those with symptoms more than 2 weeks before testing (p-value=0.893,

252 Kruskal-Wallis) (Supplemental Figure 3).

Orthogonal testing was performed on 87/88 reactive samples (where enough serum remained) using the Siemens assay against the S1/RBD target. This demonstrated an 80.5% agreement with 70/87 samples reactive. Those with lower titer levels on the Ortho Clinical assay were more likely to test negative on the Siemens assay (p=0.001, logistic regression) and older individuals were more likely to test negative (p=0.011, logistic regression); Figure 2a. There was no significant different between those with recent symptoms within 2 weeks versus those with more remote symptoms in negative results on orthogonal testing.

When comparing reactive samples from the Ortho Clinical assay with the Abbot assay targeting the nucleopcapsid antigen there was a 79.3% agreement with 69/87 samples testing positive. Those in older age groups were more likely to test negative on the Abbot assay (p=0.001, logistic regression) but there was no significant change among titer levels (p=0.177, logistic regression); Figure 2b.

A random selection of 98 samples (approximately 10%) that tested non-reactive on the Ortho Clinical assay were tested on both the Abbot and Siemens assays. All samples were negative on the additional two assays.

267 **Discussion**

Using the Ortho Clinical anti-SARS-CoV-2 antibody assay, it was determined that the seroprevalence of SARS-CoV-2 in children in Northern Virginia was as high as 8.5% (95% CI 6.9-10.3) in the fall of 2020. In contrast, the concurrently reported prevalence of SARS-CoV-2 in children in Virginia and throughout the US, based on molecular and antigen tests at the time of study completion, was around 1% [11]. Our seropositive rate of infection in children was almost 8 times the reported prevalence based on real-time viral testing.

An independently determined Northern Virginia adult seroprevalence was 4.4% in a similar study that concluded 2 months prior to this pediatric study (personal communication, author Christopher Difillipi). As of mid-October, the Centers for Disease Control reported a Virginia adult seroprevalence of 4.1% [12]. The seropositivity rate in children in this current study was more than double the reported concurrent adult seroprevalence.

279 The higher than expected pediatric seropositivity rate in our study is in part likely attributable to 280 continued viral transmission over time. In addition, early in the pandemic, it was perceived that children 281 were at reduced risk for acquiring COVID-19, either from innate protective physiologic characteristics or 282 reduced exposure [1,3]. Schools closed rapidly at the start of the pandemic with reduced communal 283 exposure. However, the unrecognized burden of mild or asymptomatic disease, resulted in testing bias 284 and under-representation of children in early testing schemes [1, 13-15]. The high SARS-CoV-2 285 seropositivity in children we identified was an unexpected finding and it has important implications for 286 this silent burden of disease and risk of transmission to and from children.

In our population, after multi-regression analysis, identified significant risk factors for seropositivity included: age-group, Hispanic ethnicity, insurance status, and residence within a multi-family dwelling or apartment without a private entrance. The highest risk belonged to children living in the same home as an individual who had tested positive for SARS-CoV-2, with an odds ratio of 22.

291 Children under 5 years were statistically more likely to be seropositive for SARS-CoV-2 compared with 292 other age groups in univariate analysis. This finding was also surprising and has implications for the need 293 for different considerations in mitigation and protection strategies in the younger age groups. Neither the 294 Spanish nor Switzerland cohorts examined children <5 years, but adolescents (ages 10-19) in Switzerland 295 were more likely to test positive for antibodies than younger children (ages 5-9) [3,4]. Young children are 296 cared for more closely by adults with possible higher risk of exposure due to prolonged physical 297 proximity and are more likely to interact with each other with less protection. Additionally, even though 298 there was an indoor mask mandate outside the home, this was only for children ≥ 10 years. Moreover,

even as public schools were closed for in-person learning, some childcare facilities for younger children remained open. However, consistent with other reports, our analyses did not indicate a significant difference in seropositivity in children cared for outside of their home, probably because greater efforts are taken to prevent transmission in childcare settings [16].

The majority of children with anti-SARS-CoV-2 antibodies in this cohort (66%) did not recall having symptoms of COVID-19. While the veracity of this is affected by recall bias, this highlights the high proportion of infections that are asymptomatic in the pediatric population and the subsequent risk of transmission to other vulnerable persons.

For seropositive individuals, mean antibody titers did not appear to differ between those with or without symptoms, recent or remote. It is interesting that for some seropositive children, symptoms were reported <2 weeks from testing as the reported kinetics of the antibody response to SARS-CoV-2 demonstrate that at least a week is necessary to mount IgM responses after onset of symptomatic disease [15]. Since COVID-19 symptoms overlap greatly with other childhood viral syndromes, it is possible that these reported symptoms were not truly caused by COVID-19 infection. It is also possible that some children with remote symptomatology had seroreversion and so were not captured in the positive cohort [17,18].

Exposure to infectious persons with COVID-19 is a well-recognized risk factor for acquiring COVID-19 and our analysis confirms this [19-22]. Consistent with other reports, the household attack rate was even higher; over 50% of children reported as exposed to a test-positive household member were seropositive [23]. Conversely, almost 60% of seropositive children had no known contact with test-positive SARS-CoV-2. This emphasizes the insidious effects of asymptomatic spread with viral shedding in symptomatic and asymptomatic individuals [24].

Ethnically and socioeconomically marginalized groups unable to shelter in place have shouldered a disproportionate burden of COVID-19 disease globally [23,26,27]. Hispanic ethnicity, the dominant minority in Northern Virginia, conferred four-fold odds of seropositivity. Publicly provided health

insurance and lack of insurance is an accepted marker for lower socioeconomic status, and families with
limited financial means are more likely to live in multi-family dwellings with a common entrance.
Significantly higher seropositivity rates in each of these groups demonstrated the disproportionate impact
of COVID-19 on the underprivileged.

327 Orthogonal testing with an antibody assay specific to the S1/RBD antigen of the spike protein 328 demonstrated high concordance. Those samples which failed to show concordance in orthogonal testing 329 to the S1/RBD exhibited very low titers to the full spike protein (Ortho Clinical assay). Future 330 consideration should be given to redefining the lower limit of detection for full spike protein antibody 331 assays as it is possible that these lower titer levels may represent cross-reactivity to conserved epitopes in 332 benign seasonal human coronaviruses [8]. In addition, some samples that may have been negative on 333 orthogonal testing may have been due to the Ortho Clinical assay also detecting IgM; however those 334 negative on orthogonal testing were not more likely to have recent symptoms consistent with COVID-19 335 within 2 weeks of antibody testing.

Children with a response to the full spike protein assay also frequently manifested antibodies to the nucleocapsid antigen. Interestingly, it was those in older age groups that more likely failed to produce a nucleocapsid antibody response, contrary to previously published data suggesting that young children may fail to elicit a nucleocapsid antibody response [7].

340 Limitations

There are several potential limitations to this investigation. Selection bias may have affected the representativeness of the regional population, as it was focused on children having blood drawn for another clinical purpose and self-referral for the study. However, these factors are accounted for in this analysis. In addition, Northern Virginia is a major metropolitan area, and so results may not be generalizable to areas that have more rural demographics. As noted, cross-reaction with other common endemic human beta-coronaviruses may result in false positive antibody results, particularly at currently

347	defined thresholds [8]. Conversely, seroreversion may produce false negative results in more remote
348	infections [23,24]. Most importantly, this study took place at a specific point in time and represents a
349	static snapshot of a dynamic event [4].

350 Conclusions

351 A much higher pediatric SARS-CoV-2 burden was found than has previously been reported in the US; 352 this rate was also higher than in adults in the same region over a similar time period. These seropositive 353 rates were following the period after the first peak of infection in the community, when schools were 354 closed, and social mitigation strategies were mandated. Contrary to reporting early in the COVID-19 355 pandemic, this study determined that children experience a significant burden of COVID-19 infection. 356 Children appear very important in the transmission of disease, including silent transmission, and with 357 such continued protection of children through social mitigation strategies and extending COVID-19 358 vaccines to children are imperative to achieving control of this pandemic.

359

360

361

362

363

364

365

366

367

368			
369			
370			

371 Acknowledgements

We recognize the efforts of all team members at the multiple study sites who have supported this 372 study and encouraged participation. This project would not have been possible without the 373 support of Dr. David Trump and the Virginia Department of Health, the help of Dr. John Farrell 374 375 and Dr. Dina Gottsman and the pediatric team at Farrell Pediatrics, Dr. Albert Brito and the 376 pediatric team at Inova Cares Clinic for Children, Dr. Sandy Chung and the pediatric team at Fairfax Pediatrics, and Dr. Christina Ulen, Ms. Lori Schubert, and the pediatric team at 377 Advanced Pediatrics, Dr. Elizabeth Yang and the pediatric teams at Pediatric Specialists of 378 379 Virginia, the pediatric teams at Inova Children's Hospital. We recognize and thank all of the participants of the study and their families; such studies can only happen because people find 380 that helping in research, especially in the midst of a pandemic, is worthwhile, and therefore, 381 382 choose join. to

References

- 1. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children United States, February 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(14):422-426.
- Pan Y, Li X, Yang G, et al. Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign. *Clin Microbiol Infect*. Published online October 6, 2020. doi:10.1016/j.cmi.2020.09.044
- Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet*. 2020;396(10250):535-544.
- 4. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*. 2020;396(10247):313-319.
- Tönshoff B, Müller B, Elling R, et al. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. *JAMA Pediatr*. Published online January 22, 2021. doi:10.1001/jamapediatrics.2021.0001
- Torres JP, Piñera C, De La Maza V, et al. SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study. *Clin Infect Dis.* Published online July 10, 2020. doi:10.1093/cid/ciaa955
- Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nat Immunol.* 2021;22(1):25-31.
- 8. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science*. 2020;370(6522):1339-1343.
- 9. https://www.fda.gov/media/136967/download (Accessed January 14, 2021)
- 10. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-testsguidelines.html. (Accessed December 30,2020)
- 11. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/childrenand-covid-19-state-level-data-report/ (accessed Nov 8, 2020)
- 12. https://covid.cdc.gov/covid-data-tracker/#trends_totalandratecases (Accessed Nov 8,2020)
- DeBiasi RL, Delaney M. Symptomatic and Asymptomatic Viral Shedding in Pediatric Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Under the Surface. *JAMA Pediatr*. Published online August 28, 2020. doi:10.1001/jamapediatrics.2020.3996
- 14. Han MS, Choi EH, Chang SH, et al. Clinical Characteristics and Viral RNA Detection in Children With Coronavirus Disease 2019 in the Republic of Korea. JAMA Pediatr. Published online August 28, 2020. doi:10.1001/jamapediatrics.2020.3988

- 15. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA*. 2020;323(22):2249-2251.
- Link-Gelles R, DellaGrotta AL, Molina C, et al. Limited Secondary Transmission of SARS-CoV-2 in Child Care Programs - Rhode Island, June 1-July 31, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(34):1170-1172.
- 17. Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. *Pediatr Infect Dis J.* 2020;39(5):355-368.
- Self WH, Tenforde MW, Stubblefield WB, et al. Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(47):1762-1766.
- Hobbs CV, Martin LM, Kim SS, et al. Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient Health Facilities and Emergency Departments Among Children and Adolescents Aged <18 Years - Mississippi, September-November 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1925-1929.
- Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2020;3(12):e2031756.
- Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 Infections in Households - Tennessee and Wisconsin, April-September 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(44):1631-1634.
- 22. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med.* 2020;383(18):1724-1734.
- 23. Bailey LC, Razzaghi H, Burrows EK, et al. Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States. *JAMA Pediatr*. Published online November 23, 2020. doi:10.1001/jamapediatrics.2020.5052
- 24. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *The Lancet Microbe*. Published online November 19, 2020. doi:10.1016/S2666-5247(20)30172-5
- 25. Leeb RT, Price S, Sliwa S, et al. COVID-19 Trends Among School-Aged Children -United States, March 1-September 19, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(39):1410-1415.
- 26. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. *JAMA*. 2020;324(3):259-269.
- DeBiasi RL, Song X, Delaney M, et al. Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region. *J Pediatr*. 2020;223:199-203.e1.

Figure Legends:

Figure 1: Wilson Score intervals for selected covariates of interest.

Figure 2. Scatterplots showing age versus titer levels of the reactive tests on the Ortho Clinical Diagnostic Vitros assay, with orthogonal testing on the Siemens assay (2a) and Abbot assay (2b). Negative tests on orthogonal testing are colored red.

Supplemental Figure 1: Pairwise plot of age vs. seropositivity rate (%). The red points represent the observed positivity rate in the cohort at each age, and the line is the predicted positivity rate produced by a quadratic regression model. The estimated seropositivity rate is higher for younger and older ages of children.

Supplemental figure 2: A multiple boxplot that shows the SARS-CoV-2 total spike protein titer levels (S/Co) for those who tested positive separated by age group and summary statistics.

Supplemental Figure 3: A multiple boxplot that showing SARS-CoV-2 total spike protein titer levels (S/Co) for those who tested positive separated by presence of symptoms and summary statistics.

Table 1: Demographic Information, Prevalence Rates, and 95% Wilson Score Intervals *Indicates an unreliable estimate due to a small count						
Variable	Category	Count	Estimated Prevalence	95% Wilson Score Intervals		
			Rate	Lower Bound	Upper Bound	
Overall	•	1038	8.5%	6.9%	10.3%	
Gender	Male	499	8.4%	6.3%	11.2%	
	Female	536	8.6%	6.5%	11.3%	
	Not Disclosed	3	0%*	0%	56.1%	
Age Group	0-5 years	182	13.7%	9.5%	19.5%	
	6 - 10 years	241	7.5%	4.8%	11.5%	
	11 - 15 years	374	5.1%	3.3%	7.8%	
	16 – 19 years	241	10.8%	7.5%	15.3%	
Race	White	717	8.2%	6.4%	10.5%	
	Black or African American	97	5.2%	2.2%	11.5%	
	Asian	106	5.7%	2.6%	11.8%	
	American Indian or Alaska Native	0				
	Native Hawaiian or Other Pacific Islander	2	0%*	0%	65.8%	
	Other	111	16.2%	10.5%	24.2%	
	Unknown/Declined	5	0%*	0%	43.4%	
Ethnicity	Not Hispanic or Latino	829	4.0%	2.8%	5.5%	
-	Hispanic or Latino	207	26.6%	21.0%	33.0%	
	Unknown	2	0%*	0%	65.8%	
Insurance	Private	834	5.3%	4.0%	7.0%	
	Medicaid	125	21.6%	15.3%	29.6%	
	Medicare	8	12.5%*	2.2%	47.1%	
	None or uninsured	20	55.0%	34.2%	74.2%	
	Other	3	33.3%*	6.1%	79.2%	
	Don't know	4	25.0%*	4.6%	69.9%	
	Military	44	6.8%	2.3%	18.2%	
Existing Medical	No	807	8.3%	6.6%	10.4%	
Comorbidity	Yes	225	8.9%	5.8%	13.3%	
	Don't Know	3	0%*	0%	56.1%	
	Missing	3	33.3%			
Symptoms	No	774	7.2%	5.6%	9.3%	
	Yes	255	11.8%	0%	65.8%	
	Unknown	6	33.3%*	9.7%	70.0%	

	Missing	3	0%		
Dwelling	Single family	001	5.0%	1 5%	7.6%
Dwennig	Multi family or apartment	115	28 70	4.570	7.070
	No Private Entrance	115	20.770	21.2/0	57.570
	Multi family or apartment	16	6 304	1 1 0/	28.30/
	Private Entrance	10	0.3 %	1.170	20.370
	Other	6	16.7%*	3.0%	56.4%
Household Member	Not Tostad	5/3	6 30/	1.5%	8 60/
Fypoguro	Tested Desitive	50	0.3%	4.3%	6.0% 64.7%
Exposure	Tested – Positive	39	5 20/	40.0%	04.7%
	Tested – Negative	413	5.5%	5.5%	7.9%
	I ested – No Results	13	0.0/%	1.19%	29.8%
	Unknown 11 Tested	4	0%*	0%	49.0%
	Missing	2	0%		
COVID-19 Exposure	No	911	5.6%	4.3%	7.3%
	Yes	106	33.0%	24.8%	42.4%
	Unknown or Missing	19	10.5%	2.9%	31.4%
	Missing	2	0%		
Reason for Visit	Specifically for COVID-19 antibody testing	504	4.6%	3.1%	6.8%
	New or acute illness or injury	193	14.0%	9.8%	19.6%
	Prevention or well visit	59	20.3%	12.0%	32.3%
	Routine visit for a prior	193	8.8%	5.6%	13.7%
	condition				
	Other	84	10.1%	5.4%	18.1%
Traveled Out of the	No	395	13.4%	10.4%	17.1%
State	Yes	642	5.5%	3.9%	7.5%
	Don't Know	1	0%*	0%	79.3%
Traveled Out of the	No	1002	8.4%	6.8%	10.3%
Country	Yes	36	11.1%	4.4%	25.3%
Child Cared for	No	729	8.2%	6.4%	10.5%
outside of Home	Yes	299	8.7%	6.0%	12.4%
	Missing	10	20.0%		
Household Member	No work outside home	383	6 3%	4 204	9.2%
Work Outside the	100 WOLK Outside Hollie			4 / 7/0	
	Essential	530	8.7%	4.2 <i>%</i>	11.4%
Home	Essential Unessential	530 121	8.7% 14.0%	4.2% 6.6% 9.0%	11.4%
Home	Essential Unessential Unknown if essential	530 121 3	8.7% 14.0%	4.2% 6.6% 9.0% 6.1%	11.4% 21.4% 79.2%
Home	Essential Unessential Unknown if essential Missing	530 121 3	0.3 % 8.7% 14.0% 33.3%* 0%	4.2 % 6.6% 9.0% 6.1%	11.4% 21.4% 79.2%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics	530 121 3 1 444	8.7% 14.0% 33.3%* 0% 4.7%	4.2 % 6.6% 9.0% 6.1% 3.1%	11.4% 21.4% 79.2% 7.1%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics Pediatric Emergency	530 121 3 1 444 175	0.3% 8.7% 14.0% 33.3%* 0% 4.7% 14.3%	4.2 % 6.6% 9.0% 6.1% 3.1% 9.9%	11.4% 21.4% 79.2% 7.1% 20.2%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics Pediatric Emergency Department	530 121 3 1 444 175	0.3% 8.7% 14.0% 33.3%* 0% 4.7% 14.3%	4.2 % 6.6% 9.0% 6.1% 3.1% 9.9%	11.4% 11.4% 21.4% 79.2% 7.1% 20.2%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics Pediatric Emergency Department Pre surgical areas	530 121 3 1 444 175 89	0.3% 8.7% 14.0% 33.3%* 0% 4.7% 14.3% 6.7%	4.2 % 6.6% 9.0% 6.1% 3.1% 9.9% 3.1%	11.4% 21.4% 79.2% 7.1% 20.2% 13.9%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics Pediatric Emergency Department Pre surgical areas Primary Care location 1	530 530 121 3 1 444 175 89 128	0.3% 8.7% 14.0% 33.3%* 0% 4.7% 14.3% 6.7% 5.5%	4.2 % 6.6% 9.0% 6.1% 3.1% 9.9% 3.1% 2.7%	11.4% 11.4% 21.4% 79.2% 7.1% 20.2% 13.9% 10.9%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics Pediatric Emergency Department Pre surgical areas Primary Care location 1 Hematology/Oncology clinic	530 530 121 3 1 444 175 89 128 57	0.3% 8.7% 14.0% 33.3%* 0% 4.7% 14.3% 6.7% 5.5% 17.5%	4.2 % 6.6% 9.0% 6.1% 3.1% 2.7% 9.8%	11.4% 11.4% 21.4% 79.2% 7.1% 20.2% 13.9% 10.9% 29.4%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics Pediatric Emergency Department Pre surgical areas Primary Care location 1 Hematology/Oncology clinic Primary Care location 2	530 530 121 3 1 444 175 89 128 57 64	0.3% 8.7% 14.0% 33.3%* 0% 4.7% 14.3% 6.7% 5.5% 17.5% 25.0%	4.2 % 6.6% 9.0% 6.1% 3.1% 9.9% 3.1% 2.7% 9.8% 16.0%	11.4% 11.4% 21.4% 79.2% 7.1% 20.2% 13.9% 10.9% 29.4% 36.8%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics Pediatric Emergency Department Pre surgical areas Primary Care location 1 Hematology/Oncology clinic Primary Care location 2 Pediatric Intensive Care Unit	530 530 121 3 1 444 175 89 128 57 64 7	0.3% 8.7% 14.0% 33.3%* 0% 4.7% 14.3% 6.7% 5.5% 17.5% 25.0% 14.3%*	4.2 % 6.6% 9.0% 6.1% 3.1% 9.9% 3.1% 2.7% 9.8% 16.0% 2.6%	11.4% 11.4% 21.4% 79.2% 7.1% 20.2% 13.9% 10.9% 29.4% 36.8% 51.3%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics Pediatric Emergency Department Pre surgical areas Primary Care location 1 Hematology/Oncology clinic Primary Care location 2 Pediatric Intensive Care Unit Pediatric inpatient units	530 530 121 3 1 444 175 89 128 57 64 7 6	0.3% 8.7% 14.0% 33.3%* 0% 4.7% 14.3% 6.7% 5.5% 17.5% 25.0% 14.3%* 0%*	4.2 % 6.6% 9.0% 6.1% 3.1% 9.9% 3.1% 2.7% 9.8% 16.0% 2.6% 0%	11.4% 11.4% 21.4% 79.2% 7.1% 20.2% 13.9% 10.9% 29.4% 36.8% 51.3% 39.0%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics Pediatric Emergency Department Pre surgical areas Primary Care location 1 Hematology/Oncology clinic Primary Care location 2 Pediatric Intensive Care Unit Pediatric inpatient units Endoscopy suite	530 530 121 3 1 444 175 89 128 57 64 7 6 10	0.3% 8.7% 14.0% 33.3%* 0% 4.7% 14.3% 6.7% 5.5% 17.5% 25.0% 14.3%* 0%* 0%*	4.2 % 6.6% 9.0% 6.1% 3.1% 9.9% 3.1% 2.7% 9.8% 16.0% 2.6% 0% 0%	11.4% 11.4% 21.4% 79.2% 7.1% 20.2% 13.9% 10.9% 29.4% 36.8% 51.3% 39.0% 27.8%
Home Enrollment Site	Essential Unessential Unknown if essential Missing Pediatric Specialists Clinics Pediatric Emergency Department Pre surgical areas Primary Care location 1 Hematology/Oncology clinic Primary Care location 2 Pediatric Intensive Care Unit Pediatric inpatient units Endoscopy suite Primary Care location 3	530 530 121 3 1 444 175 89 128 57 64 7 6 10 49	0.3% 8.7% 14.0% 33.3%* 0% 4.7% 14.3% 6.7% 5.5% 17.5% 25.0% 14.3%* 0%* 0%* 4.1%	4.2 % 6.6% 9.0% 6.1% 3.1% 9.9% 3.1% 2.7% 9.8% 16.0% 2.6% 0% 0% 1.1%	11.4% 11.4% 21.4% 79.2% 7.1% 20.2% 13.9% 10.9% 29.4% 36.8% 51.3% 39.0% 27.8% 13.7%

All other Primary Care clinics90%*0%	29.9%

	Table 2: Univariate and Multivariate Logistic Regression Results						
Covariate	Covariate p-value		Level	Level p-value			
	Univariate	Multivariate	-	Univariate	Multivariate		
Gender	0.763	0.749	Male	Base	line		
			Female	0.924	0.998		
			Not Disclosed	0.981	0.996		
Age Group	0.003	0.009	0-5 years	< 0.001	0.534		
0 1			6-10 years	0.227	0.857		
			11 - 15 years	Baseline			
			16 – 19 years	0.009	0.534		
Race	0.051	0.143	White	Baseline			
			Black or African	0.296	0.202		
			American				
			Asian	0.363	0.701		
			Native Hawaiian or	0.990	0.997		
			Other Pacific				
			Islander				
			Other	0.008	0.129		
			Unknown/Declined	0.984	0.996		
Ethnicity	< 0.001	< 0.001	Not Hispanic or	Baseline			
			Latino				
			Hispanic or Latino	< 0.001	0.001		
			Unknown	0.985	0.998		
Insurance	< 0.001 0.002		Private	Base	line		
			Medicaid	< 0.001	0.065		
			Medicare	0.383	0.448		
			None or uninsured	< 0.001	< 0.001		
			Other	0.075	0.126		
			Don't know	0.125	0.802		
			Military	0.659	0.046		
Existing	0.739	0.554	No	Base	line		
Medical			Yes	0.780	0.518		
Comorbidit			Don't know	0.981	0.996		
ies							
Symptoms	0.021	0.033	No	Base	line		
			Yes	0.025	0.025		
			Unknown	0.034	0.464		
Dwelling	< 0.001	0.005	Single-family	Base	line		
			Multi-family or	< 0.001	0.006		
			apartment – no				
			private entrance	0.071	0 52 /		
			Multi-family or	0.951	0.734		
			apartment-private				

			entrance		
			Other	0.292	0.554
Household	< 0.001	< 0.001	Not Tested	Baseline	
Member			Tested – Positive	< 0.001	< 0.001
Tested for			Tested – Negative	0.531	0.097
COVID-19			Tested – No	0.949	0.655
			Results		
			Unknown if Tested	0.986	0.997
Child	< 0.001	0.056	No	Base	line
Exposed to			Yes	< 0.001	0.114
COVID-19			Unknown	0.368	0.066
Traveled	< 0.001	0.218	No	Base	line
Out of			Yes	< 0.001	0.114
State			Unknown	0.983	0.998
Traveled	0.580	0.234	No	Base	line
Out of			Yes	0.565	0.076
Country					
Reason for	< 0.001	0.243	Specifically for	Base	line
Visit			COVID antibody		
			testing		
			New or acute	< 0.001	0.287
			illness or injury		
			Prevention or well	< 0.001	0.422
			visit		
			Routine visit for a	0.034	0.343
			prior condition	0.020	0.506
	0.044	0.000	Other	0.038	0.596
Work Out	0.041	0.222	None	Base	
of Home			Essential	0.178	0.424
			Unessential	0.008	0.173
			Yes, Not Sure II	0.105	0.657
Childeoro	0.807	0.056	No	Basa	lina
out of	0.807	0.050	No Vec	0.807	
Home			105	0.807	0.032
Household	0.239	0.439		0.230	0.283
Size	0.237	0.437		0.230	0.205
Children in	0.145	0.013		0.154	0.014
Household	0.145	0.015		0.134	0.014
Enrollment	< 0.001	0.883	Pediatric	Base	line
Site	< 0.001	0.005	Emergency	Dase	
bite			Department		
			Pre surgical areas	0.079	0.539
			Primary Care	0.017	0.899
			location 1	0.017	
			Pediatric Specialists	< 0.001	0.879
			Clinics		
			Hematology/Oncolo	0.551	0.378
			gy clinic		

Primary Care	0.055	0.543
location 2		
Pediatric Intensive	1.000	0.778
Care Unit		
Pediatric inpatient	0.988	0.995
units		
Endoscopy suite	0.985	0.993
Primary Care	0.070	0.726
location 3		
All other Primary	0.985	0.995
Care clinics		

Table 3: Odds Ratio Estimates and p-values for Chosen Covariates						
Covariate	Level	Univariate	Analysis	Multivariat	e Analysis	
		OR (95% CI)	p-value	OR (95% CI)	p-value	
Ethnicity	Not Hispanic or Latino	Basel	ine	Basel	ine	
	Hispanic or Latino	8.73 (5.51, 14.02)	< 0.001	4.22 (2.26, 7.94)	< 0.001	
	Unknown		0.985		0.994	
Insurance	Private	Basel	ine	Basel	ine	
	Medicaid	4.95 (2.91, 8.31)	< 0.001	2.45 (1.10, 5.39)	0.027	
	Medicare	2.56 (0.14, 14.86)	0.383	0.47 (0.01, 7.05)	0.628	
	None or uninsured	21.94 (8.65, 57.16)	< 0.001	11.95 (3.71, 38.43)	< 0.001	
	Other	8.98 (0.41, 95.46)	0.075	5.11 (0.22, 60.29)	0.206	
	Don't know	5.98 (0.29, 47.83)	0.125	1.93 (0.08, 19.29)	0.603	
	Military	1.31 (0.31, 3.80)	0.659	3.37 (0.73, 11.40)	0.075	
Symptoms	No	Basel	ine	Basel	ine	
	Yes	1.71 (1.06, 2.71)	0.025	1.99 (1.05, 3.72)	0.033	
	Unknown	6.41 (0.88, 33.59)	0.034	4.36 (0.27, 53.50)	0.292	
Dwelling	Single-family	Baseline		Basel	ine	
	Multi-family – no private entrance	6.44 (3.92, 10.48)	< 0.001	3.19 (1.57, 6.43)	0.001	
	Multi-family – private	1.07 (0.06, 5.42)	0.951	0.71 (0.04, 4.63)	0.765	
	Other	3.20 (0.17, 20.31)	0.292	1.15 (0.03, 17.95)	0.931	
Household	Not Tested	Basel	ine	Basel	ine	
Member COVID-19	Tested – Positive	16.57 (8.98, 31.02)	< 0.001	9.65 (3.34, 30.55)	< 0.001	
Test Results	Tested – Negative	0.84 (0.48, 1.45)	0.531	0.69 (0.35, 1.33)	0.281	
	Tested – No Results	1.07 (0.06, 5.57)	0.949	2.36 (0.12, 15.00)	0.446	
	Unknown if Tested		0.986		0.993	
Child	No	Basel	ine	Basel	ine	
Exposed to COVID-19	Yes	8.31 (5.06, 13.60)	< 0.001	2.93 (1.06, 7.45)	0.030	

	Unknown	1.98 (0.31,	0.368	3.22 (0.46,	0.160
		7.18)		13.79)	
Travel Out of	No	Basel	ine	Basel	ine
State	Yes	0.37 (0.24,	< 0.001	0.53 (0.28,	0.045
		0.58)		0.98)	
	Unknown		0.983		0.995
Number of Children		0.84 (0.66,	0.154	0.67 (0.48,	0.016
		1.06)		0.92)	



Wilson Score Intervals for Selected Categories

Siemens Test Results Among Positive Ortho Tests

Titer Level (S/Co)

Abbot Architect Results Among Positive Ortho Tests



Age (years)

Age (years)